Cargando…

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma

The p53 pathway is inactivated in the majority of human cancers. Although this perturbation frequently occurs through the mutation or deletion of p53 itself, there are other mechanisms that can attenuate the pathway and contribute to tumorigenesis. For example, overexpression of important p53 negati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrero, Ana B., Rojas, Elizabeta A., Misiewicz-Krzeminska, Irena, Krzeminski, Patryk, Gutiérrez, Norma C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187803/ https://www.ncbi.nlm.nih.gov/pubmed/27916892 http://dx.doi.org/10.3390/ijms17122003

Ejemplares similares

Factors Regulating microRNA Expression and Function in Multiple Myeloma
por: Misiewicz-Krzeminska, Irena, et al.
Publicado: (2019)

Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
por: Rojas, Elizabeta A., et al.
Publicado: (2022)

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma
por: Quwaider, Dalia, et al.
Publicado: (2017)

Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background
por: Rojas, Elizabeta A., et al.
Publicado: (2019)

Effect of Graphene Family Materials on Multiple Myeloma and Non-Hodgkin’s Lymphoma Cell Lines
por: Strojny, Barbara, et al.
Publicado: (2020)

Deregulation of DNA Double-Strand Break Repair in Multiple Myeloma: Implications for Genome Stability
por: Herrero, Ana B., et al.
Publicado: (2015)

P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.
por: Sánchez, Cristina De Ramón, et al.
Publicado: (2023)

Extracellular Vesicles in Multiple Myeloma—Cracking the Code to a Better Understanding of the Disease
por: Iskrzak, Justyna, et al.
Publicado: (2022)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)

CRL4(CRBN) E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
por: Barankiewicz, Joanna, et al.
Publicado: (2022)

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility
por: Misiewicz-Krzeminska, Irena, et al.
Publicado: (2018)

Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome
por: De Ramón, Cristina, et al.
Publicado: (2022)

Notch signaling deregulation in multiple myeloma: A rational molecular target
por: Colombo, Michela, et al.
Publicado: (2015)

RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation
por: Quwaider, Dalia, et al.
Publicado: (2022)

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma
por: Hernández-García, Susana, et al.
Publicado: (2017)

Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival
por: Herrero, Ana Belén, et al.
Publicado: (2017)

The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients
por: Barankiewicz, Joanna, et al.
Publicado: (2021)

Targeting p53 by small molecule p53 activators in multiple myeloma
por: Saha, Manujendra N, et al.
Publicado: (2012)

Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse
por: Krzeminski, Patryk, et al.
Publicado: (2016)

Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205
por: Flis, Sylwia, et al.
Publicado: (2009)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

Multiple myeloma: an overview of management
por: Bird, Sarah Anne, et al.
Publicado: (2019)

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
por: Leblay, Noémie, et al.
Publicado: (2020)

Epigenetic Deregulation of Telomere-Related Genes in Newly Diagnosed Multiple Myeloma Patients
por: Roy Choudhury, Samrat, et al.
Publicado: (2021)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
por: López-Iglesias, Ana-Alicia, et al.
Publicado: (2017)

Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2022)

Genomics of Plasma Cell Leukemia
por: Rojas, Elizabeta A., et al.
Publicado: (2022)

Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors
por: Malek, Ehsan, et al.
Publicado: (2016)

FAM46C controls antibody production by the polyadenylation of immunoglobulin mRNAs and inhibits cell migration in multiple myeloma
por: Herrero, Ana Belén, et al.
Publicado: (2020)

Deregulation of apoptosis mediators' p53 and bcl2 in lung tissue of COPD patients
por: Siganaki, Marianna, et al.
Publicado: (2010)

Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers
por: Tornesello, Maria Lina, et al.
Publicado: (2018)

P846: EXPRESSION SIGNATURE OF TP53 BIALLELIC INACTIVATION IDENTIFIES A GROUP OF MULTIPLE MYELOMA PATIENTS WITHOUT THIS GENETIC CONDITION BUT WITH DISMAL OUTCOME.
por: De Ramón, C., et al.
Publicado: (2022)

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
por: Teoh, Phaik Ju, et al.
Publicado: (2016)

Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients
por: Kulikowska de Nałęcz, Anna, et al.
Publicado: (2021)

Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
por: Martello, M., et al.
Publicado: (2022)

Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis
por: Abdi, Jahangir, et al.
Publicado: (2017)

Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications
por: Cardona-Benavides, Ignacio J., et al.
Publicado: (2021)

P841: MOLECULAR MECHANISMS OF RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA: AN IN VITRO STUDY
por: Alves, Raquel, et al.
Publicado: (2023)

An overview of pim kinase as a target in multiple myeloma
por: Liu, Zhaoyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0m37d70rnfgpussncjne3tesrv